Skip to content

Author

M. Oerlemans

6 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Nov 2026

Comprehensive geriatric assessment and frailty in transthyretin amyloid cardiomyopathy: toward more individualized and appropriate care

Transthyretin amyloid cardiomyopathy (ATTR-CM), once considered a rare disease, is now an increasingly recognized cause of heart failure. This rise in diagnoses is driven by increased awareness, the availability of non-invasive diagnostics, and the introduction of disease-modifying therapies (DMTs) in an aging populati...

Sophie I. van der Heide, A. C. Maanen, G. Lefeber et al. · 0 citations
Review Open access Oct 2026

Heterogeneity in cardiac amyloidosis care across Europe: a key opinion leader survey

Variations in ATTR-CM care across Europe highlight key areas for improvement and reveal where interventions could have the greatest impact, as differences in the number of specialized centers, variability in time to treatment initiation, and unequal access to therapies contribute to these disparities.

L. Kieviet, L. Rekker, D. Breucker et al. · 0 citations
#gene editing Review Open access Nov 2026

Transforming cardiac amyloidosis care: navigating the evolving diagnostic and therapeutic landscape

This review provides a comprehensive overview of the diagnostic pathway, including (AI-enabled) electrocardiography analysis, (non-)invasive imaging modalities, biomarkers, and genetic testing, and emerging therapeutic strategies are discussed.

L. Kieviet, D. Ahmetagić, S. Muller et al. · 0 citations
Oct 2026

Definition and Prognosis of Mitral Regurgitation in Transthyretin Amyloid Cardiomyopathy: A Multicenter International Cohort Study.

BACKGROUND In transthyretin amyloid cardiomyopathy, mitral regurgitation (MR) severity may be underestimated by conventional (semi-)quantitative echocardiographic criteria due to restrictive low-flow hemodynamics. We sought to define and validate disease-specific MR risk thresholds and compare their prognostic performa...

L. Hauptmann, C. Kronberger, S. Schwarting et al. · 0 citations
Open access Aug 2026

Clinical and Metabolic Factors as Predictors of Thirty-Day Readmission in Patients With Acute Decompensated Heart Failure With Reduced Ejection Fraction and Type 2 Diabetes Mellitus

Background Patients with heart failure with reduced ejection fraction (HFrEF) had higher readmission rates than those with normal ejection fractions, and readmission rates were highest in the first 30-days post-admission. About 30% of patients with decompensated heart failure also have type 2 diabetes mellitus (T2DM)....

R. Soerarso, D. Y. Hasanah, E. Yonas et al. · 0 citations
Aug 2026

Vitronectin-driven amyloid deposition disrupts mitochondrial homeostasis via integrin-mediated pathway in a humanized mouse model of transthyretin cardiac amyloidosis.

Modulation of integrin signalling represents a potential complementary therapeutic strategy in ATTR-CM beyond TTR suppression and actively drives cardiac amyloid deposition, and disruption of integrin αvβ3/FAK/Akt signalling links amyloid-ECM interactions to mitochondrial dysfunction.

Zeping Qiu, Yingze Fan, J. Qin et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.